Delphine O'Rourke

Healthcare Providers

• Serve as outside healthcare regulatory and contracting counsel for service providers, digital health companies, and supply chain vendors in transactions with health systems, academic medical centers and hospitals
• Advise women’s health and wellness clients including entrepreneurs, growth and mature clients on critical regulatory issues including, and not limited to, remote provision of healthcare, friendly PC models, prohibition on fee-splitting, changes of ownership, government payor requirements, corporate compliance, patient issues, partnerships and contractual arrangements, value-based contracting, private payor arrangements, licensing, accrediting and enterprise risk management
• Advise a variety of healthcare providers on compliance with the Anti-Kickback Statute, the Stark Law, OIG civil monetary penalties law, and state fraud and abuse provisions

Private Equity

• Advised Aldrich Capital Partners in its acquisition of Compliancy Group, a provider of a compliance-tracking solution that primarily tracks HIPAA compliance, serving the small to mid-size healthcare market 
• Advised Aldrich Capital Partners in its acquisition of Rhythm Management Group Corp., a minority-owned provider of remote monitoring services for cardiac patients
• Advised Great Hill Partners in its acquisition of a controlling equity stake in Clearwave Parent, Inc. at an enterprise value of $300 million
• Serve as outside counsel to private equity firms regarding portfolio companies, acquisitions of additional assets, and healthcare regulatory due diligence in connection with transactions
• Provide corporate and healthcare regulatory counsel to private equity clients in connection with formations and investments in healthcare investment funds
• Advise private equity companies regarding reimbursement strategies, Medicare and Medicaid requirements, corporate compliance, corporate practice of medicine and “friendly” PC structures
• Provide healthcare reimbursement advice and counsel to private equity clients investing in healthcare providers, health services and medical devices

Digital Health

• Advising Cano Health in its of acquisition of Doctor’s Medical Center, a provider of primary care and multi-specialty healthcare services 
• Advising York Capital Management in its minority investment in Advanced Monitoring Caregiving Inc., a telehealth company that offers remote patient monitoring services 
• Serve as outside counsel on telemedicine, fraud and abuse and corporate laws to a variety of digital health companies including in the women’s health and wellness industry
• Develop national growth legal strategies for telemedicine and tele-prescribing companies including counseling on multi-state telemedicine requirements, compliance plans, professional licensing, cross-state medical practice, Medicare and Medicaid reimbursement, physician-patient relationships, tele prescribing frameworks, fraud and abuse, and confidentiality
• Provide ongoing healthcare regulatory counsel, including fraud and abuse, reimbursement, and privacy, to artificial intelligence and clinical decision platforms in a variety of different sub-industries
• Advising Cano Health in its of acquisition of University Health Care, Inc., a provider of primary care to communities in South Florida

Healthcare Regulatory for Life Sciences Companies

• Advised Trillium Therapeutics Inc., an immuno-oncology company developing innovative therapies for the treatment of cancer, in its sale to Pfizer Inc. 

• Advised Nuvalent, Inc., a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, on their $190.6 million initial public offering 
• Advising Monte Rosa Therapeutics, Inc., a clinical-stage developing a portfolio of novel small molecule precision medicines, on their $222.3 million initial public offering
• Advising Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies for the treatment of cancer, on its $175.5 million initial public offering
• Advising Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer, on its $115 million follow-on offering
• Advising the underwriters in Sensei Biotherapeutics, a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of the next generation of immunotherapies for the treatment of cancer and infectious diseases, on its $133 million initial public offering
• Advising Kingswood Capital Management, LP, a private investment firm primarily focused on investing in businesses in transition, in connection with its acquisition of Cost Plus World Market from Bed Bath and Beyond Inc.
• Advising Collective Medical Technologies, a real-time care collaboration network used by payors and healthcare organizations to improve patient outcomes, in connection with its sale to PointClickCare Corp. for approximately $600 million
• Advising the Special Committee of the Board of Directors of NantKwest in connection with the company’s agreement to merge with ImmunityBio in a stock-for-stock transaction
• Advising Achilles Therapeutics, a biopharmaceutical company developing personalized cancer immunotherapies, on the completion of its £52.7 million Series C
• Advising a clinical-stage biotechnology company advancing new immunometabolic therapies for cancer in a Series B Preferred Stock financingAdvising a growth equity investment group in connection with the purchase of Series B Preferred Stock of a pre-clinical life sciences company studying the proteins that drive cancer and other diseases